1
|
Nargund R, Wyvratt M, Lin S, Sebhat I, Greenlee W. Annotated Bibliography of Dr. Arthur A. Patchett. J Med Chem 2023; 66:15567-15575. [PMID: 38032081 DOI: 10.1021/acs.jmedchem.3c02131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2023]
|
2
|
Naik P, Murumkar P, Giridhar R, Yadav MR. Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists—A perspective. Bioorg Med Chem 2010; 18:8418-56. [DOI: 10.1016/j.bmc.2010.10.043] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2010] [Revised: 10/14/2010] [Accepted: 10/15/2010] [Indexed: 10/18/2022]
|
3
|
Karnik SS, Husain A, Graham RM. Proceedings of the Symposium ‘Angiotensin AT1 Receptors: From Molecular Physiology to Therapeutics’: MOLECULAR DETERMINANTS OF PEPTIDE AND NON-PEPTIDE BINDING TO THE AT1 RECEPTOR. Clin Exp Pharmacol Physiol 2007; 23 Suppl 3:S58-66. [DOI: 10.1111/j.1440-1681.1996.tb02815.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
4
|
Mavromoustakos T, Moutevelis-Minakakis P, Kokotos CG, Kontogianni P, Politi A, Zoumpoulakis P, Findlay J, Cox A, Balmforth A, Zoga A, Iliodromitis E. Synthesis, binding studies and in vivo biological evaluation of novel non-peptide antihypertensive analogues. Bioorg Med Chem 2006; 14:4353-60. [PMID: 16546395 DOI: 10.1016/j.bmc.2006.02.044] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2005] [Revised: 01/23/2006] [Accepted: 02/24/2006] [Indexed: 11/17/2022]
Abstract
AT(1) antagonists (SARTANs) constitute the last generation of drugs for the treatment of hypertension, designed and synthesized to mimic the C-terminal segment of the vasoconstrictive hormone angiotensin II (AngII). They exert their action by blocking the binding of AngII on the AT(1) receptor. Up to date eight AT(1) antagonists have been approved for the regulation of high blood pressure. Although these molecules share common structural features and are designed to act under the same mechanism, they have differences in their pharmacological profiles and antihypertensive efficacy. Thus, there is still a need for novel analogues with better pharmacological and financial profiles. An example of a novel synthetic non peptide AT(1) antagonist which devoids the classical template of SARTANs is MM1. In vivo studies showed that MMK molecules, which fall in the same class of MM1, had a significant antihypertensive (40-80% compared to the drug losartan) activity. However, in vitro affinity studies showed that losartan has considerably higher affinity. The theoretical docking studies showed that MM1 acts on the same site of the receptor as losartan. They exert hydrophobic interactions with amino acid Val108 of the third helix of the AT(1) receptor and other hydrophobic amino acids in spatial vicinity. In addition, losartan favours multiple hydrogen bondings between its tetrazole group with Lys199. These additional interactions may in part explain its higher in vitro binding affinity.
Collapse
Affiliation(s)
- T Mavromoustakos
- Institute of Organic and Pharmaceutical Chemistry, National Hellenic Research Foundation, Athens, Greece.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Ismail MAH, Barker S, Abou el-Ella DA, Abouzid KAM, Toubar RA, Todd MH. Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists. J Med Chem 2006; 49:1526-35. [PMID: 16509571 DOI: 10.1021/jm050232e] [Citation(s) in RCA: 108] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A series of novel quinazolin-4-ones was designed and their molecular modeling simulation fitting to a new HipHop 3D pharmacophore model using CATALYST was examined. Several compounds showed significant high simulation fit values. The designed compounds were synthesized and eight of them were biologically evaluated in vitro using an AT1 receptor binding assay, where compound XX competed weakly against radiolabeled Sar1Ile8-angiotensin II (Ang II) binding, compounds XIV and XXII showed moderate competition, and compound XXV showed almost equal ability to displace radiolabeled Sar1Ile8-Ang II binding to AT1 receptors as losartan. In vivo biological evaluation study of compounds XIV, XXII, and XXV on both normotensive and hypertensive rats revealed that compound XXV demonstrated higher hypotensive and antihypertensive activity than the reference compound losartan. To obtain a highly active compound from a candidate set of only eight tested compounds illustrates the power and utility of our pharmacophore model.
Collapse
Affiliation(s)
- Mohamed A H Ismail
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, ElKhalifa ElMaamoon St., 11566, Abbasseya, Cairo, Egypt.
| | | | | | | | | | | |
Collapse
|
6
|
Zoumpoulakis P, Daliani I, Zervou M, Kyrikou I, Siapi E, Lamprinidis G, Mikros E, Mavromoustakos T. Losartan's molecular basis of interaction with membranes and AT1 receptor. Chem Phys Lipids 2004; 125:13-25. [PMID: 14625072 DOI: 10.1016/s0009-3084(03)00053-7] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Physicochemical methods were used to study the thermal and dynamic changes caused by losartan in the membrane bilayers. In addition, molecular modeling was implemented to explore its topography both in membranes and AT(1) receptor. Its incorporation resulted in the modification of thermal profile of dipalmitoyl phosphatidylcholine (DPPC) bilayers in a concentration dependent way up to 20mol% as it is depicted from the combination of differential scanning calorimetry (DSC) and MAS data. In particular, the presence of losartan caused lowering of the phase transition temperature and abolishment of the pretransition. T(1) experiments revealed the location of the drug into the membrane bilayers. The use of a combination of biophysical methods along with docking experiments brought out a possible two-step mechanism which involves incorporation of losartan at the interface of membrane bilayers and diffusion in the upper parts of AT(1) receptor helices IV-VII.
Collapse
Affiliation(s)
- P Zoumpoulakis
- Institute of Organic and Pharmaceutical Chemistry, National Hellenic Research Foundation, 48 Vas. Constantinou Avenue, 11635, Athens, Greece
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Datar PA, Desai PV, Coutinho EC. A 3D-QSAR of Angiotensin II (AT1) Receptor Antagonists Based on Receptor Surface Analysis. ACTA ACUST UNITED AC 2004; 44:210-20. [PMID: 14741030 DOI: 10.1021/ci0341520] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A hypothetical receptor surface model has been constructed for a set of 38 AT1 antagonists using activity data of each molecule as a weight in the building of the receptor surface. The best model was derived by optimizing various parameters such as atomic partial charges, surface fit, and the manner of representation of electrostatics on the surface. Descriptors such as van der Waals energy, electrostatic energy, and total nonbonded energy were used individually or in combination to derive a family of quantitative structure-activity relationship equations using G/PLS as the statistical method.
Collapse
Affiliation(s)
- Prasanna A Datar
- Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai 400 098, India
| | | | | |
Collapse
|
8
|
Schmidt B, Drexler H, Schieffer B. Therapeutic effects of angiotensin (AT1) receptor antagonists: potential contribution of mechanisms other than AT1 receptor blockade. Am J Cardiovasc Drugs 2004; 4:361-8. [PMID: 15554721 DOI: 10.2165/00129784-200404060-00004] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Blockade of the renin-angiotensin system improves morbidity and mortality of patients with cardiovascular diseases, e.g. arterial hypertension, renal failure, following myocardial infarction and in congestive heart failure. The angiotensin II type 1 (AT(1)) receptor antagonists (angiotensin receptor blockers; ARBs), i.e. losartan, eprosartan, irbesartan and valsartan were developed by computer-based molecule design. Early observations already indicate that the ARBs elicit pleiotropic effects developing anti-aggregatory, anti-inflammatory and anti-mitogenic effects independent from their actions at the AT(1) receptor. Losartan metabolism indicates a number of known active intermediates and pointed to further interactions of these derivatives with other receptors and cellular signaling systems. Here we discuss a compilation of detailed pharmacokinetic and pharmacodynamic data of active metabolites of ARBs indicating their mode of action and suggest novel therapeutic implications. The clinical observations that ARBs elicit potencies in patients with cardiovascular diseases via the regulation of inflammatory, growth and homeostatic factors lead us to focus on specific, reactive metabolites, which hold potential for future indications and possible drug interactions in cardiovascular diseases.
Collapse
Affiliation(s)
- Boris Schmidt
- Institute for Organic Chemistry, Technische Universität Darmstadt, Darmstadt, Germany
| | | | | |
Collapse
|
9
|
Schmidt B, Schieffer B. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. J Med Chem 2003; 46:2261-70. [PMID: 12773029 DOI: 10.1021/jm0204237] [Citation(s) in RCA: 94] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Boris Schmidt
- Clemens Schöpf Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Petersenstrasse 22, Germany.
| | | |
Collapse
|
10
|
Yoo SE, Kim SK, Lee SH, Yi KY, Lee DW. A comparative molecular field analysis and molecular modelling studies on pyridylimidazole type of angiotensin II antagonists. Bioorg Med Chem 1999; 7:2971-6. [PMID: 10658603 DOI: 10.1016/s0968-0896(99)00245-x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
A large number of compounds known as "AII (Angiotensin II) antagonists" have been developed for the treatment of various heart diseases such as hypertension, congestive heart failure, and chronic renal failure. Most of the currently known AII receptor antagonists share a similar chemical structure, consisting of nitrogen atoms, a lipophilic alkyl side chain and an acidic group. As a new series, we have designed and synthesized various pyridylimidazole derivatives. In this report we would like to discuss the structure-activity relationship of these series of compounds using the comparative molecular field analysis (CoMFA) methods. We could come up with a good CoMFA model (cross-validated and conventional r2 values equal to 0.702 and 0.991, respectively) and the validity of the model was confirmed by synthesizing and measuring their biological activity of additional 6 compounds suggested by the model. This result provides additional information on the structural requirement for structurally diverse group of AII receptor antagonists.
Collapse
Affiliation(s)
- S E Yoo
- Bio-Organic Science Division 5, Korea Research Institute of Chemical Technology, Daejon, South Korea.
| | | | | | | | | |
Collapse
|
11
|
Cramer RD, Poss MA, Hermsmeier MA, Caulfield TJ, Kowala MC, Valentine MT. Prospective identification of biologically active structures by topomer shape similarity searching. J Med Chem 1999; 42:3919-33. [PMID: 10508440 DOI: 10.1021/jm990159q] [Citation(s) in RCA: 93] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The principle of bioisosterism-similarly shaped molecules are more likely to share biological properties than are other molecules-has long helped to guide drug discovery. An algorithmic implementation of this principle, based on shape comparisons of a single rule-generated "topomer" conformation per molecule, had been found to be the descriptor most consistently predictive of similar biological properties, in retrospective studies, and also to be well-suited for searching large (>10(12)) "virtual libraries" of potential reaction products. Therefore a prospective trial of this shape similarity searching method was carried out, with synthesis of 425 compounds and testing of them for inhibition of binding of angiotensin II (A-II). The 63 compounds that were identified by shape searching as most similar to any of four query structures included all of the seven compounds found to be highly active, with none of the other 362 structures being highly active (p < 0.001). Additional consistent relations (p < 0.05) were found, among all 425 compounds, between the degree of shape similarity to the nearest query structure and the frequency of various levels of observed activity. Known "SAR" (rules specifying structural features required for A-II antagonism) were also regenerated within the biological data for the 63 shape similar structures.
Collapse
Affiliation(s)
- R D Cramer
- Tripos, Inc., 1699 South Hanley Road, St. Louis, Missouri 63366, and Bristol-Myers Squibb, Princeton, New Jersey 08546, USA
| | | | | | | | | | | |
Collapse
|
12
|
Mavromoustakos T, Kolocouris A, Zervou M, Roumelioti P, Matsoukas J, Weisemann R. An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations. J Med Chem 1999; 42:1714-22. [PMID: 10346924 DOI: 10.1021/jm980499w] [Citation(s) in RCA: 97] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Losartan is the first recently approved drug against hypertension disease that competes with the biological action of angiotensin II (AII) at the AT1 receptor. Its design was based on the mimicry of the C-terminal segment of AII. Due to the biological significance of Losartan, its structure elucidation and conformational properties are reported as determined by NMR spectroscopy and computational analysis. In addition, molecular modeling of the peptide Sarmesin [Sar1Tyr(OMe)4AII], a competitive antagonist of AII, was also developed based on NMR and computational analysis data. Sarmesin's C-terminal was used as a template for superimposition with specific molecular features of interest in the structure of Losartan such as the conformation of biphenyltetrazole, the n-butyl chain, and the orientation of hydroxymethylimidazole relative to the biphenyl template. The major conclusions derived from this study are the following: (a) Sarmesin, like the AII superagonist [Sar1]AII, adopts a conformation which keeps in close proximity the key amino acids Sar1 (or Arg2)-Tyr(OMe)4-His6-Phe8. (b) Losartan favors a low-energy conformation in which imidazole and tetrazole rings are placed in the opposite site relative to the spacer phenyl ring plane; the hydroxymethyl group is placed away from the spacer phenyl ring, the alkyl chain is oriented above the spacer phenyl ring, and the two phenyl rings deviate approximately 60 degrees from being coplanar. (c) Overlay of the C-terminal region of Sarmesin with Losartan using equivalent groups revealed an excellent match. (d) Interestingly, the matching between enantiomeric structures of Losartan was not equivalent, proposing that the chirality of this molecule is significant in order to exert its biological activity. These findings open a new avenue for synthetic chemists to design and synthesize peptidomimetic drugs based on the C-terminal segment of the proposed model of Sarmesin. The new candidate drug molecules are not restricted to structurally resemble Losartan as the design is hitherto focused.
Collapse
Affiliation(s)
- T Mavromoustakos
- Institute of Organic and Pharmaceutical Chemistry, The National Hellenic Research Foundation, Vas. Constantinou Ave. 48, 11635 Athens, Greece.
| | | | | | | | | | | |
Collapse
|
13
|
Miller MD, Sheridan RP, Kearsley SK. SQ: a program for rapidly producing pharmacophorically relevent molecular superpositions. J Med Chem 1999; 42:1505-14. [PMID: 10229621 DOI: 10.1021/jm9806143] [Citation(s) in RCA: 84] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A new method SQ has been developed to provide fast, automatic, and objective pairwise three-dimensional molecular alignments. SQ uses an atom-based clique-matching step followed by an alignment scoring function that has been parametrized to recognize pharmacologically relevant atomic properties. Molecular alignments from SQ are consistent with known drug-receptor interactions. We demonstrate this with six pairs of receptor-ligand complexes from the Brookhaven Protein Data Bank. The SQ-generated alignment of one isolated ligand onto another is shown to approximate the alignment of the ligands when the receptors are superimposed. SQ appears to be better than its predecessor SEAL (Kearsley and Smith, Tetrahedron Comput. Methodol. 1990, 3, 615-633) in this regard. SQ has been tailored so that, given one molecule as a probe, it can be used to routinely scan large chemical databases for which precomputed conformations have been stored. The SQ score, a measure of 3D similarity of each candidate molecule to the probe, can be used to rank compounds for the purposes of chemical screening. We demonstrate this with three probes (a thrombin inhibitor, an HIV protease inhibitor, and a model for angiotensin II). In each case SQ can preferentially select from the MDDR database other compounds with the same activity as the probe. We further show, using the angiotensin example, how SQ can identify topologically diverse compounds with the same activity.
Collapse
Affiliation(s)
- M D Miller
- Department of Molecular Systems, Merck Research Laboratories, Sumneytown Pike, West Point, Pennsylvania 19486, USA
| | | | | |
Collapse
|
14
|
Ellingboe JW, Collini MD, Quagliato D, Chen J, Antane M, Schmid J, Hartupee D, White V, Park CH, Tanikella T, Bagli JF. Metabolites of the angiotensin II antagonist tasosartan: the importance of a second acidic group. J Med Chem 1998; 41:4251-60. [PMID: 9784100 DOI: 10.1021/jm970690q] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Described in this paper is the synthesis and pharmacological activity of five metabolites of the angiotensin II antagonist tasosartan (1). Of particular interest is the effect of the additional acidic group of the enol metabolite (8) on activity. As suggested by the structural-activity relationship of other angiotensin II antagonist series, a second acidic group can improve receptor binding activity but decrease in vivo activity after oral dosing. The metabolic introduction of a second acidic group in tasosartan bypasses this problem and contributes to the excellent profile of the compound. A molecular modeling study provides a rationale for the role of the enol group of 8 in AT1 receptor binding.
Collapse
Affiliation(s)
- J W Ellingboe
- Divisions of Chemical Sciences, Cardiovascular and Metabolic Disorders, and Structural Biology, Wyeth-Ayerst Research, CN 8000, Princeton, New Jersey 08543, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Takeuchi Y, Shands EF, Beusen DD, Marshall GR. Derivation of a three-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor. J Med Chem 1998; 41:3609-23. [PMID: 9733486 DOI: 10.1021/jm9700171] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Constrained systematic search was used in an exhaustive conformational analysis of a structurally diverse set of substance P (SP) antagonists to identify a unique hypothesis for their bound conformation at the neurokinin-1 receptor. In this conformation, two aromatic groups essential for high affinity adopt a perpendicular or edge-on arrangement. This pharmacophore hypothesis for the receptor-bound conformation was used in a comparative molecular field analysis (CoMFA) of an expanded set of SP antagonists, and the predictive ability of the resulting three-dimensional quantitative structure-activity relationship (3D-QSAR) was evaluated against a test set of SP antagonists different from those in the training set. This CoMFA model based on the Constrained Search alignment yielded significant cross-validated, conventional, and predictive r2 values equal to 0.70, 0.93, and 0.82, respectively. For comparison, the SP antagonists were forced into an alternative poorer alignment in which the two aromatic rings were parallel and then subjected to a CoMFA analysis. Both the parallel and perpendicular arrangements of the aromatic rings are seen in X-ray structures of SP antagonists and have been proposed as candidates for the receptor-bound conformation. The parallel (or stacked) conformation yielded a poorer correlation with a cross-validated r2 = 0.57, a conventional r2 = 0.90, and a predictive r2 = 0.78. Our results indicate that although both alignments could generate a reasonable CoMFA correlation, the stacked conformation is unlikely to be the receptor-bound conformation, as the covalent structure of the antagonists precludes a common geometry in which the aromatic rings are stacked.
Collapse
Affiliation(s)
- Y Takeuchi
- Center for Molecular Design and Department of Computer Science, Washington University, St. Louis, Missouri 63110-1012, USA
| | | | | | | |
Collapse
|
16
|
Mills JE, Perkins TD, Dean PM. An automated method for predicting the positions of hydrogen-bonding atoms in binding sites. J Comput Aided Mol Des 1997; 11:229-42. [PMID: 9263850 DOI: 10.1023/a:1007900527102] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Hydrogen bonds are the most specific, and therefore predictable of the intermolecular interactions involved in ligand-protein binding. Given the structure of a molecule, it is possible to estimate the positions at which complementary hydrogen-bonding atoms could be found. Crystal-survey data are used in the design of a program, HBMAP, that generates a hydrogen-bond map for any given ligand, which contains all the feasible positions at which a complementary atom could be found. On superposition of ligands, the overlapping regions of their maps represent positions of receptor atoms to which each molecule can bind. The certainty of these positions is increased by the incorporation of a larger number and diversity of molecules. In this work, superposition is achieved using the program HBMATCH, which uses simulated annealing to generate the correspondence between points from the hydrogen-bonding maps of the two molecules. Equivalent matches are distinguished on the basis of their steric similarity. The strategy is tested on a number of ligands for which ligand-protein complexes have been solved crystallographically, which allows validation of the techniques. The receptor atom positions of thermolysin are successfully predicted when the correct superposition is obtained.
Collapse
Affiliation(s)
- J E Mills
- Department of Pharmacology, University of Cambridge, U.K
| | | | | |
Collapse
|
17
|
Belvisi L, Bravi G, Catalano G, Mabilia M, Salimbeni A, Scolastico C. A 3D QSAR CoMFA study of non-peptide angiotensin II receptor antagonists. J Comput Aided Mol Des 1996; 10:567-82. [PMID: 9007690 DOI: 10.1007/bf00134180] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A series of non-peptide angiotensin II receptor antagonists was investigated with the aim of developing a 3D QSAR model using comparative molecular field analysis descriptors and approaches. The main goals of the study were dictated by an interest in methodologies and an understanding of the binding requirements to the AT1 receptor. Consistency with the previously derived activity models was always checked to contemporarily test the validity of the various hypotheses. The specific conformations chosen for the study, the procedures invoked to superimpose all structures, the conditions employed to generate steric and electrostatic field values and the various PCA/PLS runs are discussed in detail. The effect of experimental design techniques to select objects (molecules) and variables (descriptors) with respect to the predictive power of the QSAR models derived was especially analysed.
Collapse
Affiliation(s)
- L Belvisi
- Organic and Industrial Chemistry Department, C.N.R. (National Research Council), University of Milan, Italy
| | | | | | | | | | | |
Collapse
|
18
|
de Laszlo SE, Glinka TW, Greenlee WJ, Ball R, Nachbar RB, Prendergast K. The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT1 and AT2 receptor antagonists. Bioorg Med Chem Lett 1996. [DOI: 10.1016/0960-894x(96)00116-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Wexler RR, Greenlee WJ, Irvin JD, Goldberg MR, Prendergast K, Smith RD, Timmermans PB. Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem 1996; 39:625-56. [PMID: 8576904 DOI: 10.1021/jm9504722] [Citation(s) in RCA: 225] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- R R Wexler
- DuPont Merck Pharmaceutical Company, Wilmington, Delaware, USA
| | | | | | | | | | | | | |
Collapse
|
20
|
Joseph MP, Maigret B, Scheraga HA. Proposals for the angiotensin II receptor-bound conformation by comparative computer modeling of AII and cyclic analogs. INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH 1995; 46:514-26. [PMID: 8748712 DOI: 10.1111/j.1399-3011.1995.tb01607.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A conformational search using high-temperature molecular dynamics on angiotensin II(AII) and on two cyclic S-S bridged analogs, namely [Hcy3,5]AII and [Cys3,5]AII, in conjunction with a cluster analysis based on the similarities of the three-dimensional patterns of the binding and activation elements, had led to putative AII receptor-bound conformations. These conformations are characterized by a compact folded shape of the peptide backbone, and by particular relative positions of the four pharmacophore groups, namely the aromatic moieties of the Tyr4, His6 and Phe8 residues, and the C-terminal carboxyl group. This compact folded shape, arising from attractive electrostatic interactions between the desolvated N- and C-terminal groups, is similar to the crystallographically determined conformation of AII bound to the antibody Fab receptor.
Collapse
Affiliation(s)
- M P Joseph
- Laboratory of Theoretical Chemistry, University of Nancy I, Faculty of Sciences, Vandoevre-lès-Nancy, France
| | | | | |
Collapse
|
21
|
Affiliation(s)
- S M Green
- Center for Molecular Design, Washington University, St. Louis, MO 63130-4899, USA
| | | |
Collapse
|
22
|
Noda K, Saad Y, Kinoshita A, Boyle TP, Graham RM, Husain A, Karnik SS. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 1995; 270:2284-9. [PMID: 7530721 DOI: 10.1074/jbc.270.5.2284] [Citation(s) in RCA: 116] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
To identify specific interactions between either the tetrazole or carboxylate pharmacophores of non-peptide antagonists and the rat AT1 receptor, 6 basic residues were examined by site-directed mutagenesis. Three of the mutants (H183Q, H256Q, and H272Q) appeared to be like wild type. Lys102 and Arg167 mutants displayed reduced binding of the non-peptide antagonist losartan. Examination of their properties employing group-specific angiotensin II analogues indicated that their effects on binding were indirect. Interestingly, the affinity of losartan was not altered by a K199Q mutation, but the same mutation reduced the affinity of angiotensin II, the antagonist [Sar1,Ile8]angiotensin II, and several carboxylate analogues of losartan. An Ala199 substitution reduced the affinity of peptide analogues to a larger extent as compared to the affinity of losartan. Thus, the crucial acidic pharmacophores of angiotensin and losartan appear to occupy the same space within the receptor pocket, but the protonated amino group of Lys199 is not essential for binding the tetrazole anion. The binding of the tetrazole moiety with the AT1 receptor involves multiple contacts with residues such as Lys199 and His256 that constitute the same subsite of the ligand binding pocket. However, this interaction does not involve a conventional salt bridge, but rather an unusual lysine-aromatic interaction.
Collapse
Affiliation(s)
- K Noda
- Department of Molecular Cardiology, Cleveland Clinic Foundation, Ohio 44195-5069
| | | | | | | | | | | | | |
Collapse
|
23
|
Cohen NC, Tschinke V. Generation of new-lead structures in computer-aided drug design. PROGRESS IN DRUG RESEARCH. FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG. PROGRES DES RECHERCHES PHARMACEUTIQUES 1995; 45:205-243. [PMID: 8545538 DOI: 10.1007/978-3-0348-7164-8_6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Affiliation(s)
- N C Cohen
- Research Department, Pharmaceutical Division, CIBA-GEIGY Limited, Basel, Switzerland
| | | |
Collapse
|
24
|
Underwood DJ, Strader CD, Rivero R, Patchett AA, Greenlee W, Prendergast K. Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. CHEMISTRY & BIOLOGY 1994; 1:211-21. [PMID: 9383393 DOI: 10.1016/1074-5521(94)90013-2] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND The family of G protein coupled receptors is the largest and perhaps most functionally diverse class of cell-surface receptors. Due to the difficulty of obtaining structural data on membrane proteins there is little information on which to base an understanding of ligand structure-activity relationships, the effects of receptor mutations and the mechanism(s) of signal transduction in this family. We therefore set out to develop a structural model for one such receptor, the human angiotensin II receptor. RESULTS An alignment between the human angiotensin II (type 1; hAT1), human beta 2 adrenergic, human neurokinin-1, and human bradykinin receptors, all of which are G protein coupled receptors, was used to generate a three-dimensional model of the hAT1 receptor based on bacteriorhodopsin. We observed a region within the model that was congruent with the biogenic amine binding site of beta 2, and were thus able to dock a model of the hAT1 antagonist L-158,282 (MK-996) into the transmembrane region of the receptor model. The antagonist was oriented within the helical domain by recognising that the essential acid functionality of this antagonist interacts with Lys199. The structural model is consistent with much of the information on structure-activity relationships for both non-peptide and peptide ligands. CONCLUSIONS Our model provides an explanation for the conversion of the antagonist L-158,282 (MK-996) to an agonist by the addition of an isobutyl group. It also suggests a model for domain motion during signal transduction. The approach of independently deriving three-dimensional receptor models and pharmacophore models of the ligands, then combining them, is a powerful technique which helps validate both models.
Collapse
|